Last reviewed · How we verify
Mepolizumab IV
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system.
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).
At a glance
| Generic name | Mepolizumab IV |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | IL-5 antagonist monoclonal antibody |
| Target | IL-5 (Interleukin-5) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-5 is a key cytokine responsible for eosinophil recruitment, activation, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven diseases such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)
Common side effects
- Headache
- Injection site reactions
- Pyrexia
- Back pain
- Fatigue
Key clinical trials
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists (PHASE1)
- Mepolizumab in Nasal Polyposis (PHASE2)
- Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma (PHASE3)
- Intravenous Mepolizumab In Children With Eosinophilic Esophagitis (PHASE2)
- Japanese Phase 1 Study of Mepolizumab (PHASE1)
- Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome (PHASE1, PHASE2)
- Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepolizumab IV CI brief — competitive landscape report
- Mepolizumab IV updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI